small molecule

DORIBAX

DORIPENEM

Loss of exclusivity—loss of exclusivity

CompanyShionogi →See this company's full patent-cliff portfolio

Drug detail

Brand name	DORIBAX
Active ingredient	DORIPENEM
Strength	500MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	INJECTABLE
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	October 2007
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.